APA (7th ed.) Citation

J, R., K, E., B, W., HJ, K., CM, S., EJ, E., . . . RB, L. (2024). In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts. Experimental hematology, 132, 104176. https://doi.org/10.1016/j.exphem.2024.104176

Chicago Style (17th ed.) Citation

J, Randall, et al. "In Vivo Activity of the Second-generation Proteasome Inhibitor Ixazomib Against Pediatric T-cell Acute Lymphoblastic Leukemia Xenografts." Experimental Hematology 132 (2024): 104176. https://doi.org/10.1016/j.exphem.2024.104176.

MLA (9th ed.) Citation

J, Randall, et al. "In Vivo Activity of the Second-generation Proteasome Inhibitor Ixazomib Against Pediatric T-cell Acute Lymphoblastic Leukemia Xenografts." Experimental Hematology, vol. 132, 2024, p. 104176, https://doi.org/10.1016/j.exphem.2024.104176.